百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

休市中 08-14 16:08:36

211.200

-8.200

-3.74%

最高218.200	最低210.400	成交量453.52万
今开216.200	昨收219.400	日振幅3.56%
总市值3,257亿	流通市值3,014亿	总股本15.42亿
成交额9.64亿	换手率0.32%	流通股本14.27亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":211.2,"timestamp":1786694916006,"preClose":219.4,"halted":0,"volume":4535229,"delay":0,"changeRate":-0.03737465815861448,"floatShares":1427000000,"shares":1542000000,"eps":1.49095617373563,"marketStatus":"休市中","change":-8.2,"latestTime":"08-14 16:08:36","open":216.2,"high":218.2,"low":210.4,"amount":964390952,"amplitude":0.035552,"askPrice":211.4,"askSize":58600,"bidPrice":211.2,"bidSize":25100,"shortable":3,"etf":0,"ttmEps":3.3738768784086006,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":219.4,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.6005364273941306,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"BOM.HK","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":287.71,"timestamp":1786690800000,"preClose":292.18,"halted":0,"volume":5627000,"delay":0,"premium":"-36.91"},"impliedVol":0.3824,"impliedVolPercentile":0.1786},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2659352175","title":"每周股票复盘：百济神州（688235）授出40,764股ADS受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2659352175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659352175?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:10","pubTimestamp":1786813818,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，百济神州报收于287.71元，较上周的299.33元下跌3.88%。本周，百济神州8月11日盘中最高价报314.85元。百济神州当前最新总市值4437.31亿元，在化学制药板块市值排名1/149，在两市A股市值排名31/5207。本周关注点公司公告汇总：授出40,764股美国存托股份的受限制股份单位，相当于529,932股普通股。百济神州有限公司董事会审计委员会将于2026年8月26日审议及批准公司截至2026年6月30日止六个月的中期业绩，并将根据香港上市规则刊发相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU0828237510.HKD","BK1161","688235","LU1303224171.USD","KURE","LU0307460666.USD","LU1969619763.USD","LU0228659784.USD","LU1770034418.SGD","LU1719994722.HKD","BK1583","BK1500","LU0588546209.SGD","LU1251922891.USD","BK1588","06160","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146940","title":"JPMorgan Chase & Co.增持百济神州(06160)411.972万股 每股作价约219.79港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146940","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659146940?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:18","pubTimestamp":1786706314,"startTime":"0","endTime":"0","summary":"8月11日，JPMorgan Chase & Co.增持百济神州(06160)411.972万股，每股作价219.7851港元，总金额约为9.05亿港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260814/20260814192003_51980.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260814/20260814192003_51980.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2357305700.SGD","IE00BLSP4452.SGD","LU0211326839.USD","LU1119994496.HKD","IYF","UYG","EWH","TRUF","LU1894683348.USD","LU2328871848.SGD","JPO","LU0689472784.USD","JPMO","LU0323591593.USD","JPMLL","KURE","LU2417539215.USD","IE00BWXC8680.SGD","IXG","IE00BKVL7J92.USD","06160","FTXO","LU1116320737.USD","LU0211331839.USD","LU2552382215.SGD","688235","BK4566","JPX","XLF","LU1629891620.HKD","LU2462157665.USD","SG9999002232.USD","LU0828237510.HKD","LU2237443465.HKD","IE00BZ1G4Q59.USD","LU2237443978.SGD","TFNS","LU1496350502.SGD","IYG","BK4533","LU0320765489.SGD","BK1583","VFH","PGF","IE00BN8TJ469.HKD","LU2552382132.HKD","ONC","LU2106854487.HKD","FNCL","KBWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103504937","title":"百济神州：审计委员会将于2026年8月26日审议截至6月30日中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1103504937","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103504937?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:25","pubTimestamp":1786699531,"startTime":"0","endTime":"0","summary":"百济神州有限公司8月14日公告称，其董事会审计委员会计划于2026年8月26日审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并按照香港联合交易所有限公司证券上市规则对外发布相关业绩。公司已于2026年8月5日公布了截至2026年6月30日止三个月及六个月的中期业绩，并以提交表格10-Q的形式向美国证券交易委员会备案。公司表示，将在2026年8月26日审计委员会会议后正式发布符合香港上市规则的中期业绩报告，供投资者参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144349557","title":"百济神州：摩根大通增持，好仓比例升至9.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144349557","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144349557?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:16","pubTimestamp":1786698991,"startTime":"0","endTime":"0","summary":"摩根大通于2026年8月11日以每股均价219.7851港元买入百济神州股份411.97万股，涉资约9.05亿港元。摩根大通此次增持前持有百济神州好仓1.25亿，占比8.77%；增持后持股量为1.29亿，好仓比例升至9.05%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112026","title":"小摩：在百济神州H股的持股比例升至9.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112026","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659112026?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:12","pubTimestamp":1786698771,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","BK1500","KURE","LU2328871848.SGD","06160","LU0228659784.USD","LU0307460666.USD","LU1719994722.HKD","BK1161","LU1303224171.USD","LU0828237510.HKD","LU0588546209.SGD","BK1583","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659299118","title":"创新药概念集体回调 康方生物（09926）跌6.85%、维亚生物（01873）跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659299118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659299118?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:51","pubTimestamp":1786686711,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念集体回调，康方生物 跌6.85%，维亚生物跌6.33%，思路迪医药股份跌6.15%，恒瑞医药跌5.10%，晶泰控股跌4.88%，凯莱英跌4.67%，亚盛医药跌4.04%，药明康德跌3.94%，百济神州跌3.92%。西南证券表示，CXO+创新药放量领涨，8-9月有望迎来业绩+临床数据共振。从产业链的角度，CXO板块投融资改善明显，26H1中国/全球医疗健康投融资分别676.47亿元/2416.43亿元，ADC、多肽、细胞基因治疗等新药物形式赛道持续火热，头部CXO公司海外订单复苏明显。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU1794554557.SGD","BK1588","LU0348766576.USD","LU1251922891.USD","LU2045819591.USD","BK1576","LU0634319403.HKD","06978","LU0359202008.SGD","LU0708995583.HKD","LU0307460666.USD","LU0561508036.HKD","LU2242644610.SGD","LU2399975544.HKD","KURE","LNGR","LU0828237510.HKD","06821","IE00B543WZ88.USD","159992","LU0228659784.USD","09926","LU2778985437.USD","LU0348784397.USD","02359","06855","LU1770034418.SGD","06160","LU1961090484.USD","IE00B5MMRT66.SGD","01244","LU2476274720.SGD","MEDX","BK1574","02228","LU2476274308.USD","01276","BK1617","LU0572944931.SGD","01873","LU0327786744.USD","LU0348827113.USD","LU0052750758.USD","LU0359201612.USD","LU1720050803.USD","LU0348783233.USD","LU1719994722.HKD","LU0588546209.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","LU0348766576.USD","LU0348783233.USD","LU1961090484.USD","03933","AGIX","LU0561508036.HKD","LU2476274720.SGD","01789","01477","601066","LU0348784397.USD","BK1585","LU0540923850.HKD","LU2778985437.USD","IE00B5MMRT66.SGD","LU1770034418.SGD","LU2476274308.USD","LU0417516738.SGD","LU1303224171.USD","02268","02196","BK1515","VTHR","AIPO","LU0348735423.USD","QTOC","02228","LU0348827113.USD","LU0417516571.SGD","02367","06160","01099","BK1197","09688","09926","LU0348825331.USD","LU0634319403.HKD","LU0828237510.HKD","01530","KCE","LU1719994722.HKD","06821","CHAT","LU2328871848.SGD","LU0640798160.USD","KURE","BK1500","BK1191","SG9999004311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168507","title":"百济神州（688235）披露授出受限制股份单位公告，8月13日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168507?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:03","pubTimestamp":1786629800,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，百济神州报收于292.18元，较前一交易日下跌0.5%，最新总市值为4506.25亿元。该股当日开盘291.0元，最高301.96元，最低290.11元，成交额达20.95亿元，换手率为6.14%。近日，公司披露港股公告显示，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划向三百六十二名承授人授出合计40,764股美国存托股份的受限制股份单位，相当于529,932股普通股，约占公司当前已发行股份总数的0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1251922891.USD","06160","LU1303224171.USD","KURE","LU0307460666.USD","BK1161","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","BK1588","BK1500","LU0588546209.SGD","BK1583","BK0239","LU0228659784.USD","LU1969619763.USD","LU0828237510.HKD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152904","title":"别慌！机构资金都流向了这里！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152904","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659152904?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:23","pubTimestamp":1786623796,"startTime":"0","endTime":"0","summary":"今天（8月13日），A股早盘三大指数集体高开，CPO等板块全线走强，“易中天”强势上涨，封板个股比比皆是。然而，下午2点左右，画风突变，上午追高的资金，午后被悉数套牢，截至收盘，仅创新药一枝独秀。那么，科技冲高回落，医药逆势爆发，这究竟发生了什么？今天这篇文章，笔者将逐一拆解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840675371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840675371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","BK1500","BK1588","399300","CPI","06160","82846","BK1147","LU0307460666.USD","BK1583","LNGR","03188","LU0588546209.SGD","LU1770034418.SGD","LU0828237510.HKD","02827","BD","BK4007","IBBQ","BK1161","03130","LU1251922891.USD","OCS","LU2328871848.SGD","02846","159982","07233","KURE","06978","MEDX","LU0228659784.USD","LU1719994722.HKD","LU1969619763.USD","83130","BK1574","83188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141637235","title":"百济神州：欧雷强减持美股","url":"https://stock-news.laohu8.com/highlight/detail?id=1141637235","media":"港股披露","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141637235?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:14","pubTimestamp":1786612491,"startTime":"0","endTime":"0","summary":"欧雷强于2026年8月12日以每股均价27.55美元卖出百济神州71.36万股普通股，涉资约1965.96万美元。欧雷强此次减持前持有百济神州好仓5956.21万股，占比3.86%；减持后持股量为5884.85万股，好仓比例降至3.82%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115413834","title":"百济神州（06160）授出40,764份美国存托股份受限制股份单位 占已发行股本约0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1115413834","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115413834?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:56","pubTimestamp":1786611391,"startTime":"0","endTime":"0","summary":"8月13日，百济神州有限公司公告称，其董事会薪酬委员会已于2026年8月7日根据公司2016期权及激励计划向362名承授人授出共计40,764份美国存托股份的受限制股份单位。上述ADS相当于529,932股普通股，占本公告日期公司已发行股份总数的约0.03%。本次授予不收取任何对价。授出当日，百济神州ADS的收市价为每股348.27美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659137609","title":"百济神州(06160)授出合共40764股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2659137609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659137609?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:56","pubTimestamp":1786611374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划的条款授予362名承授人合共40,764股美国存托股份受限制股份单位。该等受限制股份单位相当于529,932股股份，约占本公告之日公司发行股份总数的0.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","688235","BK1161","BK1500","BK0239","BK1583","06160","LU0307460666.USD","LU0228659784.USD","LU0828237510.HKD","BK1588","BK4588","LU0588546209.SGD","BK4526","KURE","LU2328871848.SGD","LU1770034418.SGD","LU1969619763.USD","LU1303224171.USD","LU1251922891.USD","LU1719994722.HKD","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992720","title":"吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992720","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992720?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:25","pubTimestamp":1786447500,"startTime":"0","endTime":"0","summary":"8月11月，A股、港股大幅回调，医药资产受大市影响整体冲高回落，其中创新药产业链韧性凸显，批量成功收红。成份股再鼎医药领涨5.28%，权重龙头百济神州涨2.63%斩获6连阳，股价创年内新高！基金管理人评估的药ETF华宝的风险等级为R3-中风险，适宜平衡型及以上的投资者，港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型及以上的投资者。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-11/doc-inimyaaf7389173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["KURE","BK1500","BK1161","06160","603087","LU1719994722.HKD","BK1588","LU1969619763.USD","LU1770034418.SGD","LU1251922891.USD","BK4585","BK0239","BK4139","LU0307460666.USD","LU1303224171.USD","BK1583","LU0228659784.USD","LU0828237510.HKD","BK4588","159316","159828","688235","FLHK","ONC","LU2328871848.SGD","LU0588546209.SGD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993724","title":"百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993724","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658993724?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:35","pubTimestamp":1786437325,"startTime":"0","endTime":"0","summary":"8月10日，由百济神州与安进公司共同负责中国（不含港澳台地区）商业化开发的安泰适（注射用塔拉妥单抗）正式投入临床使用。截至8月10日，全国17个城市29家医疗机构已开出首批处方。据悉，塔拉妥单抗为首个且目前唯一获批的靶向DLL3和CD3的T细胞衔接器（TCE），于8月7日启动供应，首批复盖全国80个城市、超200家医疗机构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837896326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837896326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","KURE","BK4139","BK1583","ONC","LU0828237510.HKD","688235","BK1588","LU1303224171.USD","LU0588546209.SGD","06160","LU0307460666.USD","LU0228659784.USD","LU2328871848.SGD","LU1969619763.USD","LU1770034418.SGD","BK4585","LU1719994722.HKD","BK4588","BK4526","LU1251922891.USD","BK1161","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CANC","LU1548497426.USD","BK4512","IE00BFMHRM44.USD","LU1861219969.SGD","LU1720051017.SGD","BBH","LU0109394709.USD","LU0889565916.HKD","LU1854104046.USD","LU0348723411.USD","ON","LU1861215975.USD","688235","KURE","BK1588","LU2360107325.USD","PTH","LU1854103824.USD","RVMD","BK4588","LU0320765992.SGD","IE0002141913.USD","BK0239","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU1770034418.SGD","LU1983260115.SGD","06160","LU2298322129.HKD","LU1720051108.HKD","IE00BD6J9T35.USD","LU1251922891.USD","LU2357305700.SGD","BK4585","LU1978683503.SGD","BK1583","LU0724618433.USD","LU0124384867.USD","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0588546209.SGD","LU1861214812.USD","IDNA","BK4605","IE00BZ199S13.USD","IE0009354923.USD","IE0009355771.USD","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658842961","title":"浦银国际证券：上调百济神州目标价至361.4元，给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658842961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658842961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:22","pubTimestamp":1786422143,"startTime":"0","endTime":"0","summary":"浦银国际证券有限公司季昶阳近期对百济神州进行研究并发布了研究报告《泽布替尼远期收入重估，后续管线待验证》，上调百济神州目标价至361.4元，给予买入评级。　　百济神州　　维持“买入”评级，上调百济神州美股、港股、A股目标价至447.5美元、270.2港元、人民币361.4元。2Q26泽布替尼全球销售12.48亿美元，同比增长31%，其中美国销售8.93亿美元，同比增长31%。本文数据来源于浦银国际证券有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100017227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","06160","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","IE00BZ08YR35.GBP","KURE","09969","LU1303224171.USD","BK1583","LU1993786604.SGD","LU1226287792.SGD","LU2328871848.SGD","03692","BK1161","IE00B5MMRT66.SGD","MEDX","IE00BZ08YS42.EUR","BK1617","02268","02359","06855","LU0072913022.USD","LU1226287875.USD","LU1951186391.HKD","LNGR","02228","LU2039709279.SGD","LU1813983027.USD","BK1576","LU2125910500.SGD","159992","LU0315179316.USD","BK1500","LU0880133367.SGD","BK1588","06978","LU1226288170.HKD","LU1152091168.USD","IE00BZ08YT58.USD","09688","HK0000320223.HKD","IE00B031HY20.USD","01548","06160","HK0000306685.HKD","IBBQ","LU2488822045.USD","LU0326950275.SGD","02410","01093","LU2242644610.SGD","IE00B543WZ88.USD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965691?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BBH","IE00B4R5TH58.HKD","688235","IE00BJJMRZ35.SGD","LU0109394709.USD","BK1161","VXUS","BK1500","BK0239","BK1583","06160","LU0307460666.USD","LU0228659784.USD","LU0889565916.HKD","LU0828237510.HKD","BK1588","RVMD","BK4588","IE0002141913.USD","IDNA","IE00BFTCPJ56.SGD","LU0588546209.SGD","IE0009354923.USD","IE0009355771.USD","PTH","LU0320765992.SGD","BK4526","KURE","LU2328871848.SGD","KCAI","LU1770034418.SGD","IE00BJT1NW94.SGD","LU1303224171.USD","CANC","LU1969619763.USD","LU1251922891.USD","LU1719994722.HKD","BK4139","IE00B2B36J28.USD","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658196566?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","IE0009355771.USD","LU2468319806.SGD","LU1061106388.HKD","LU0122379950.USD","LU2242646821.SGD","06160","LU0058720904.USD","AMGN","KURE","BK4526","BIB","LU2242652126.USD","BK4588","LU1770034418.SGD","PJP","BK1161","LU1023059063.AUD","BK1583","LU2112291526.USD","BK1500","LU0289739699.SGD","BK4599","LU0307460666.USD","LU0109394709.USD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0828237510.HKD","IBB","PBE","BBH","IBBQ","IE00B2B36J28.USD","LU1983299246.USD","LU2089984988.USD","TBXU","BK4533","LU0228659784.USD","SG9999001440.SGD","BK4566","LU1969619763.USD","BK4139","LU1571399168.USD","IE0002141913.USD","BK4534","BK4585","LU0588546209.SGD","BK1588","IE00B4R5TH58.HKD","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179530386","title":"异动解读｜百济神州盘中上涨3.94%，与Revolution Medicines达成RAS联合治疗临床合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1179530386","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179530386?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:32","pubTimestamp":1786411964,"startTime":"0","endTime":"0","summary":"8月11日，百济神州盘中上涨3.94%，报221.6港元，成交额1.48亿港元。消息面上，公司8月10日宣布与专注癌症药物研发的生物科技公司Revolution Medicines达成临床合作协议，双方将共同评估百济神州部分临床阶段肿瘤候选药物与Revolution四款RAS激活态抑制剂的联合治疗方案，瞄准传统\"不可成药\"靶点。此前公司调研中曾披露，已停止原Pan-KRAS抑制剂开发，转向Pan-RAS分子胶降解剂新方向，此次合作进一步强化其RAS赛道布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":0.121},{"period":"3month","weight":0.1779},{"period":"6month","weight":0.0125},{"period":"1year","weight":0.1416},{"period":"ytd","weight":0.1779}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.027621},{"month":2,"riseRate":0.5,"avgChangeRate":0.032126},{"month":3,"riseRate":0.125,"avgChangeRate":-0.059409},{"month":4,"riseRate":0.5,"avgChangeRate":0.034277},{"month":5,"riseRate":0.375,"avgChangeRate":-0.043816},{"month":6,"riseRate":0.375,"avgChangeRate":0.001624},{"month":7,"riseRate":0.875,"avgChangeRate":0.102282},{"month":8,"riseRate":0.875,"avgChangeRate":0.06236},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.07577}],"exchange":"SEHK","name":"百济神州","nameEN":"BEONE MEDICINES"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}